==== Front Int J OncolInt. J. OncolIJOInternational Journal of Oncology1019-64391791-2423D.A. Spandidos 3006685810.3892/ijo.2018.4508ijo-53-04-1557ArticlesDownregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis Gan Bin-Liang 1*He Rong-Quan 1*Zhang Yu 2Wei Dan-Ming 2Hu Xiao-Hua 1Chen Gang 2 1 Department of Medical Oncology 2 Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. ChinaCorrespondence to: Dr Dan-Ming Wei, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, E-mail: danmingwei08@163.comDr Xiao-Hua Hu, Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, E-mail: gxmuhxh@163.com* Contributed equally 10 2018 30 7 2018 30 7 2018 53 4 1557 1579 29 1 2018 02 7 2018 Copyright: © Gan et al.2018This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.Recent studies have indicated that homeobox A3 (HOXA3) functions as a carcinogen in colon cancer and the methylation level of HOXA3 is significantly increased in lung adenocarcinoma (LUAD) tissues. However, at least to the best of our knowledge, few studies to date have been performed on HOXA3 in non-small cell lung cancer (NSCLC). Therefore, further studies on HOXA3 expression in NSCLC and the potential regulatory mechanisms are urgently required. In this study, HOXA3 expression in 55 tissues of cases of NSCLC and corresponding non-lung cancer tissues was detected by reverse transcription-quantitative PCR (RT-qPCR). In addition, the clinical significance of HOXA3 expression in NSCLC was evaluated using the Cancer Genome Atlas (TCGA) database. Bioinformatics analysis was then performed to elucidate the potential molecular mechanisms of action of HOXA3. Furthermore, the potential target microRNAs (miRNAs or miRs) of HOXA3 were predicted using miRWalk2.0. Based on Gene Expression Omnibus (GEO) and TGCA databases, standardized mean difference (SMD) and sROC methods were used for meta-analyses of the expression of potential target miRNAs of HOXA3 in NSCLC to evaluate their association with HOXA3. The results revealed that the HOXA3 expression levels in NSCLC, LUAD and lung squamous cell carcinoma (LUSC) were 0.1130±0.1398, 0.1295±0.16890 and 0.0906±0.0846, respectively. These values were all decreased compared with the normal tissues (0.1877±0.1975, 0.2337±0.2405 and 0.1249±0.0873, respectively, P<0.05). The TCGA database also revealed the low expression trend of HOXA3. The downregulation of HOXA3 may play an important role in the progression and the poor prognosis of LUAD. The TCGA database also suggested that HOXA3 in LUAD and LUSC tissues exhibited certain mutational levels. In addition, the methylation levels in the NSCLC, LUAD and LUSC tissues significantly increased [NSCLC: fold change (FC), 1.3226; P<0.001; LUAD: FC, 1.2712; P<0.001; and LUSC: FC, 1.3786; P<0.001]. According to the analyses using the Kyoto Encyclopedia of Genes and Genomes (KEGG), we found that the co-expression HOXA3 genes were mainly associated with the focal adhesion signalling pathway and the ECM-receptor interaction signalling pathway. Furthermore, the predicted miRNA, miR-372-3p, exhibited a high expression in both the NSCLC and LUAD tissues (P<0.05). On the whole, the findings of this study indicate that low HOXA3 expression may play a certain role in LUAD; however, its association with LUSC still requires further investigation. HOXA3 function may be achieved through different pathways or target miRNAs. However, the specific underlying mechanisms need to be confirmed through various functional studies. homeobox A3lung adenocarcinomareverse transcription-quantitative PCRco-expressionmechanism ==== Body Introduction The most recent data indicate that lung cancer remains the type of cancer with the highest prevalence among men and women and is also one of the most common causes of cancer-related mortality (1). Approximately 1.82 million cases of lung cancer are newly diagnosed globally each year, and approximately 1.37 million individuals succumb to the disease (2–4). Based on the histological classification, lung cancers are divided into 2 types: Non-small cancer lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for 85% of all lung cancer cases (5). NSCLS includes a number of histological subtypes, including lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma (LCC). LUAD is one of the main subtypes of NSCLC (6). Despite in-depth studies and significant progress being made in lung cancer treatment in recent decades (7–10), comprehensive clinical evaluation and in-depth molecular mechanistic studies are still required. Therefore, further investigations of the pathological mechanisms of NSCLC are warranted. Thus, the screening of novel functional genes and targets in NSCLC may provide basic data and a preliminary theoretic basis for further studies on the pathogenesis of NSCLC. The homeobox (HOX) gene family is composed of 39 genes. These genes play critical roles in normal embryonic development by encoding transcription factors. The HOX gene family is divided into 4 groups: HOXA, HOXB, HOXC and HOXD. These genes localize to different chromosomal regions. The human HOXA gene cluster localizes to chromosome 7. There are 12 genes, including HOXA1 to HOXA11 and HOXA13 (11–13). The HOXA gene cluster plays important roles in colorectal cancer, leukaemia, pancreatic cancer, oral squamous cell carcinoma and lung cancer (14–18). For HOXA3, only one study suggests that it nat be used as a biomarker of LUAD. This study was conducted by Daugaard et al (19). These researchers used a DNA methylation microarray to compare the genome-wide methylation patterns between tumour and tumour-adjacent lung tissues from 4 patients with LUAD and identified 74 differential methylation regions (DMRs). Through methylation sensitive-high resolution melting (MS-HRM) analyses, 18 DMRs were selected for validation in 52 LUAD tissues and 32 cancer-adjacent lung tissues. Finally, this study confirmed and validated 15 DMRs, including HOXA3, that could be used as biomarkers of LUAD (19). However, studies on the clinical significance and regulatory mechanisms of HOXA3 expression in NSCLC are still lacking. Therefore, further studies are urgently required to examine HOXA3 expression in NSCLC and to investigate the potential regulatory mechanisms in order to provide new insight into the pathogenic mechanisms of NSCLC. In this study, we used reverse transcription-quantitative PCR (RT-qPCR) to detect HOXA3 expression in NSCLC and normal lung tissues. HOXA3 expression in NSCLC was validated using the Gene Expression Profiling Interactive Analysis (GEPIA) database. In addition, informatics analysis methods, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI), were performed to investigate the potential molecular mechanisms of action of HOXA3. Furthermore, the potential target microRNAs (miRNAs or miRs) of HOXA3 were predicted using miRWalk2.0. The expression levels of miRNAs were validated using the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TGCA) databases. The study design is presented in Fig. 1. Materials and methods Clinical samples A total of 55 tissues of cases of clinical NSCLC and cancer-adjacent lung tissues were collected (from January, 2012 to February, 2014) at the Department of Pathology of The First Affiliated Hospital of Guangxi Medical University (Nanning, China). Among these 55 patients, 32 cases were diagnosed with LUAD, and 23 cases were diagnosed with LUSC. There were 41 men and 14 women. Patients were 23–90 years of age with a mean age of 56.9 years. Among these 55 cases, tumours in 39 cases were larger than 3 cm. Table I summarizes the detailed clinicopathological data of all the patients. Samples were fixed in formalin and embedded in paraffin. This research programme was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All participants signed informed consent forms. All samples were diagnosed by 2 pathologists (G.C. and D.-M.W.) independently using the double-blind method. Detection of HOXA3 expression by RT-qPCR HOXA3 expression in NSCLC samples was detected by RT-qPCR which was performed as previously described (20–22). Total RNA was extracted from the tumour and cancer-adjacent normal tissues using the RNeasy reagent (Qiagen, Shanghai, China). The RNA concentration was measured using NanoDrop2000 (Thermo Fisher Scientific, Wilmington, DE, USA). Total RNA was reverse transcribed (10 µl reaction system) using a reverse transcription kit (ABI, Life Technologies, Carlsbad, CA, USA) to obtain cDNA for RT-qPCR. SYBR-Green (Shanghai GeneCore BioTechnologies Co., Ltd., Shanghai, China) was used to perform RT-qPCR and the distinctiveness of the PCR product was differentiated based on melting curve (23–26). RT-qPCR was carried out using the following conditions: preheating for 10 min at temprature 95°C; and then repeating 40 cycles in temperature 95°C for 15 sec and 60 sec at 60°C. The primer sequences of HOXA3 were as follows: Upstream, TCATTTAAGAGCGCCTGGACA and downstream primer, GAGCTGTCGTAGTAGGTCGC. Using GAPDH as an internal reference gene and the primer sequence were as follows: Upstream, 5′-TGGTCCCTGCTCCTCTAAC-3′, downstream primer, 5′-GGCTCAATGGCGTACTCTC-3′. The relative expression level of HOXA3 in this study was calculated using the 2−ΔΔCq (27) formula (28, 29). Retrieval of TCGA data GEPIA (http://gepia.cancer-pku.cn/) is a visualization website based on TCGA data and contains differential gene expression between cancer and non-cancer, and analysis of the association between gene expression and overall survival (OS) or disease-free survival (DFS) and clinical stages (Stage). Survival analyses were performed using the log-rank test (also known as Mantel-Cox test) for hypothesis tests and calculation of the hazard ratio (HR) and 95% confidence interval (95% CI). Keywords, such as 'HOXA3', 'LUAD' and 'LUSC', were searched in GEPIA to retrieve data of the differential expression of HOXA3 in NSCLS, LUAD, LUSC and normal lung tissues, as well as information regarding the association between HOXA3 and clinical stages and prognostic survival. The keywords 'lung' and 'HOXA3' were searched in the cBioPortal (http://www.cbioportal.org/) website to retrieve genetic alteration data of HOXA3 in LUAD and LUSC. Data were obtained from microarray detection and RNA sequencing. In addition, DNA methylation data in LUAD and LUSC were downloaded from the Cancer Genome Atlas (TCGA: https://cancergenome.nih.gov/abouttcga/overview) database. HOXA3 methylation data in LUAD and LUSC were screened. HOXA3 co-expression genes To investigate the intrinsic mechanisms of HOXA3 expression in NSCLC tissues, we acquired HOXA3-associated co-expression genes from the MEM (http://biit.cs.ut.ee/mem) and cBioPortal databases. In MEM, when the score/P-value was smaller, the association between that gene and HOXA3 was more significant. The results of 2 gene probes were extracted from MEM based on a P-value <0.0001, and the results were used for intersection. On the other hand, Pearson's correlation analysis was performed in cBioPortal to calculate the correlation between co-expression genes and HOXA3. When the absolute value of the Pearson's correlation coefficient was larger, the correlation was stronger. This study selected genes with an absolute value of the Pearsons' correlation coefficient >0.3 in NSCLC, LUAD and LUSC. Finally, the intersection results between MEM and cBioPortal were obtained and used for further analyses. The overlapping genes were confirmed using a Venn diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/). Bioinformatics analyses In this study, we used bioinformatics analyses to preliminarily investigate the molecular mechanisms of action of HOXA3 in NSCLC. The final overlapping genes in MEM and cBioPortal were used for GO and KEGG analyses in David v6.7 (http://david.abcc.ncifcrf.gov/) to elucidate the enrichment of genes in biological processes and signalling pathways. PPI analyses were performed in STRING v10.5 (https://string-db.org/cgi/input.pl?input_page_show_search=on&UserId=HJJhhNv8hYyf&sessionId=Ce1Dx9pYDluc) to validate the protein interaction association to hypothesize the pathways through which HOXA3 carries out its functions in NSCLC. The construction of the functional network was performed using Cytoscape 3.5.0 software and ClueGO plugin. Prediction and preliminary validation of target miRNAs of HOXA3 The prediction of target miRNAs of HOXA3 was performed in miRWalk2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/). miRWalk2.0 contains 12 on-line target gene prediction tools: Pictar2, miRWalk, miRMap, DIANA microT v4, PITA, miRanda, RNA22, mirBridge, miRDB, RNAhybrid, miRNAMap and TargetScan. miRNAs that were present in >8 software results were used as candidate miRNAs for further analyses. The microarray results of differentially expressed miRNAs in lung cancer were searched in the GEO database and downloaded. The following search formula was employed: (lung OR pulmonary OR respiratory OR bronchi OR bronchioles OR alveoli OR pneumocytes OR 'air way') AND (cancer OR carcinoma OR tumor OR neoplas* OR malignan* OR adenocarcinoma) AND (microRNA OR miRNA OR 'micro RNA' OR 'small temporal RNA' OR 'noncoding RNA' OR ncRNA OR 'small RNA'). We included microarray data containing expression data of miRNAs in lung cancer tissues and normal lung tissues and a sample number >3 into this study. Microarray data that did not conform to this condition were excluded. In addition, miRNA expression data for the LUAD, LUSC and normal lung tissues were extracted from the TCGA database. The mean value ± standard deviation (means ± SD) of the expression of potential target miRNAs in tumour and non-tumour tissues in each microarray was calculated. The random effects model was used to calculate the standardized mean difference (SMD) in STATA 2.0 software to evaluate the expression trend of miRNAs in NSCLC and plot the forest plot. In addition, analyses using the sROC method were performed to further validate the expression trend of miRNAs in NSCLC. Statistical analyses Statistical analyses of the experimental data were performed using SPSS 22.0 software (IBM, New York, NY, USA). The HOXA3 expression levels detected by RT-qPCR were expressed as the means ± SD and the Mann-Whitney test was used to determine significance. The normal distribution was determined using the single-sample K-S test. The comparison of the association between the HOXA3 expression level and the patient clinicopathological characteristics, and the comparison of mean values of 2 factors were performed using the independent sample t-test when variances were homogeneous. When variances were not homogeneous, rank sum statistical analysis was performed. The comparison of the mean values of multiple factors was performed using one-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test, with a default P-value of 0.05. The differences in HOXA3 expression levels between the NSCLC and normal lung tissues were further validated using the calculation of the area under the ROC curve. The Kaplan-Meier curve method was performed to analyse the association between the HOXA3 expression level and NSCLC patient survival. Pearson's correlation analysis was used to calculate the correlation between two genes. GraphPad Prism was used to generate the scatter plot. Meta-analysis of target miRNAs in NSCLC and normal lung tissues was performed using the STATA 12.0 software. P<0.05 in all analytic results indicated that the differences exhibited statistical significance. Results HOXA3 expression in NSCLC For NSCLC, the HOXA3 expression level in the cancer tissues was 0.11±0.14 and the fold change (FC), 0.60 (FC is the fold change of HOXA3 expression in tumour and non-tumour adjacent tissue). Compared with the normal lung tissues (0.19±0.20, P=0.006), HOXA3 expression was significantly decreased (P=0.006; Fig. 2A). The median of the HOXA3 level was 0.06 and the FC, 0.5 (control, 0.12; P=0.008). The area under the ROC curve (AUC) of low HOXA3 expression in NSCLC was 0.65 (95% CI: 0.54, 0.76; P=0.008, Fig. 2B). Therefore, a low HOXA3 expression may have some value in the occurrence of NSCLC. A low HOXA3 expression was not significantly associated with the clinicopathological characteristics (Table I). In addition, in LUAD, the mean expression level of HOXA3 was 0.13±0.17 and the FC, 0.55. HOXA3 expression was significantly decreased in LUAD compared with the cancer-adjacent normal tissues (0.24±0.24, P=0.023) (Fig. 2C and Table I). The median of the HOXA3 level was 0.08 and the FC, 0.62 (control, 0.13; P=0.034). The AUC of downregulated HOXA3 expression in LUAD was 0.66 (95% CI: 0.52, 0.80; P=0.035) (data not shown). Further analyses revealed that the HOXA3 level in smokers (0.06±0.04) was reduced compared with that in non-smokers (0.186±0.20, P=0.025) (Fig. 2D and Table I). The AUC of downregulated HOXA3 in the smoking group was 0.70 (95% CI: 0.51, 0.89; P=0.069) (data not shown). The combination of the above-mentioned data analyses demonstrated that the downregulation of HOXA3 expression in LUAD was significant. In addition, HOXA3 expression in LUAD may be associated with smoking, but did not exhibit a significant association with other clinicopathological characteristics. The analyses of the LUSC group alone revealed that HOXA3 expression differed significantly between the cancer tissues and non-cancer tissues (cancer, 0.09±0.08 vs. control, 0.12±0.09, P=0.034, FC, 0.72) (Fig. 2E and Table I). The median of the HOXA3 level was 0.06 and the FC, 0.5 (control, 0.12; P=0.113). The AUC of the low HOXA3 level in the LUSC group was 0.64 (95% CI: 0.47, 0.81; P=0.113) (data not shown). The low expression of HOX3A in LUSC was not significantly associated with disease progression. In addition, the GEPIA data revealed that HOXA3 expression in LUAD (483 cases) was also significantly decreased compared with the normal lung tissues (347 cases) and exhibited a low expression trend in LUSC (LUSC, 486 cases; normal, 338 cases) (Fig. 3A). These results were consistent with the results of RT-qPCR. However, the association between the HOXA3 expression level and the pathological stage did not exhibit an obvious pattern (Fig. 3B). We also acquired information regarding the association between the HOXA3 expression level and the survival of patients with NSCLC, LUAD and LUSC. Patients with NSCLC with a low HOXA3 expression exhibited a better OS [HR (high), 1.3; P=0.0035] (Fig. 4A, panel a). Thus, a low HOXA3 expression may be a protective factor of OS in patients with NSCLC. However, further analysis demonstrated that HOXA3 was not significantly associated with the DFS of patients with NSCLC (Fig. 4A, panel d). The analyses of OS in the LUAD group alone demonstrated that patients with a high HOXA3 expression exhibited an HR of 1.4 (P=0.042) (Fig. 4A, panel b), suggesting that a high HOXA3 level may be a risk factor for the prognosis of LUAD. However, the HOXA3 expression levels did not exhibit obvious predictive values as regards the DFS of patients with LUAD (Fig. 4A, panel e). In addition, the association between HOXA3 and the prognosis of patients LUSC was not statistically significant (Fig. 4A, panels c and f), and this may require further investigation. Furthermore, based on the microarray and RNA sequencing technologies, the sequencing results of 520 patients with LUAD revealed that the genetic alteration rates of HOXA3 were 5% (24/520) and 11% (59/520). In addition, the sequencing results of 504 patients LUSC suggested that the genetic alteration rates of HOXA3 were 5% (25/504), 7% (35/504) and 4% (18/504). Although the genetic alternation rates obtained using different methods differed, the final results all confirmed that HOXA3 harboured genetic alterations in the LUAD and LUSC populations (Fig. 4B). On the other hand, the methylation level of HOXA3 in the NSCLC tissues was 0.57±0.21 (FC, 1.32; P<0.001; Fig. 5A), with an AUC value of 0.72 (95% CI: 0.68, 0.76; P<0.001, Fig. 5D). The methylation level in the LUAD tissues was 0.56±0.20 (FC, 1.27; P<0.001; Fig. 5B), and an AUC value of 0.70 (95% CI: 0.64, 0.76; P<0.001, Fig. 5E). The methylation level in the LUSC tissues was 0.58±0.21 (FC, 1.38; P<0.001; Fig. 5C), and the AUC value was 0.74 (95% CI: 0.68, 0.79; P<0.001, Fig. 5F) (Table II). Compared with the normal tissues (NSCLC, 0.43±0.11; LUAD, 0.44±0.11; LUSC, 0.42±0.11), these levels were all significantly upregulated. HOXA3 co-expression genes Based on MEM, 11,488 and 4,730 HOXA3 co-expression mRNA genes detected by 2 independent gene probes were obtained. The intersection between the results of 2 gene probes was collected, and a total of 1,709 more convincing co-expression mRNA genes were extracted. The data from cBioPortal revealed 3,600 and 2,676 co-expression mRNA genes in the NSCLC group and the LUAD group, respectively. Finally, the search results of the NSCLC group and the LUAD group in MEM and cBioPortal were processed using the crossing method (data not shown). In total, 293 and 213 genes were obtained, respectively, for further analysis. Bioinformatics analyses GO and KEGG analyses were performed on 293 and 213 genes in DAVID, and PPI network analyses were performed in STRING. The results from GO analysis revealed that genes in the NSCLC group mainly participated in biological processes, such as the regulation of cell migration; the regulation of apoptosis; and the regulation of programmed cell death; cellular components, such as insoluble fraction, membrane fraction, and extracellular matrix; and molecular functions, such as sequence-specific DNA binding, enzyme activator activity, and phosphatidylinositol-3,4,5-tri-sphosphate binding (Figs. 6 and 8A–C, and Table III). The results of KEGG pathway analyses suggested that HOXA3 may be involved in the functional regulation of 22 signalling pathways in the NSCLC group. The most important pathways were focal adhesion, pathways in cancer, and the TGF-β signalling pathway (Figs. 7 and 8D, and Table IV). In addition, genes in the LUAD group mainly participated in biological processes, such as the regulation of cell migration, regulation of apoptosis and the regulation of programmed cell death. Significant enrichment also occurred in cellular components and molecular functions; for example, insoluble fraction and membrane fraction in cellular components and sequence-specific DNA binding and enzyme activator activity in molecular functions (Figs. 9 and 11A–C, and Table V). The analytical results in the LUAD group suggested that HOXA3 may be involved in the biological regulation of 15 signalling pathways. Of these pathways, the most significant pathways were focal adhesion and ECM-receptor interaction (Figs. 10 and 11D, and Table VI). In PPI analyses, 278 interaction nodes were obtained in the NSCLC group (Fig. 12A). The genes with the top 10 overall scores are presented in Table VII. The results of interaction network analyses demonstrated that MAPK1, EGFR, DCN and CFTR represented key genes in these networks. In addition, genes enriched in 'Focal adhesion' were used for PPI analyses, and a total of 13 interaction nodes were obtained (Fig. 12B). The genes with the top 10 overall score are presented in Table VIII. The results suggested that MAPK1, EGFR, TNC and COL1A1 were key genes in this pathway. PPI analyses were also performed on genes in the LUAD group, and the results generated 129 protein interaction nodes (Fig. 13). The nodes with the top 10 overall scores are presented in Table IX. The protein interaction network suggested that MAPK1, EGFR, CFTR and GLI3 were key nodes in these interaction networks. Genes in the LUAD group that were enriched in 'Focal adhesion' were used for PPI analyses, and 14 protein interaction network nodes were also obtained. The result was the same as that for the NSCLC group. MAPK1, EGFR, TNC and COLIA1 were key genes in these pathways (refer to Fig. 12B and Table X). Analytic results revealed that genes in the NSCLC and LUAD groups all participated in the regulation of the 'Focal adhesion' pathway. MAPK1 and EGFR played key roles in NSCLC and LUAD, whereas MAPK1, EGFR, CFTR and GLI3 represented key genes in the 'Focal adhesion' pathway. Therefore, these 4 genes were analysed further. Based on TCGA data, the results of Pearson's correlation analysis revealed that the 4 genes, EGFR, MAPK1, COL1A1 and TNC, all exhibited a potential positive correlation with HOXA3 expression in NSCLC (Fig. 14). In the LUAD group, only COL1A1 and TNC exhibited a possible positive correlation with HOXA3 (Fig. 15C and D). Prediction and preliminary validation of HOXA3 target miRNAs HOXA3 had 3 target miRNAs that passed the target prediction. Based on GEO microarray search and TCGA database, the random effects model was used for meta-analyses of the expression of these 3 miRNAs in NSCLC tissues. The results revealed that the expression of hsa-miR-372-3p was significantly increased in the NSCLC and LUAD tissues, but only exhibited an increasing trend in the LUSC tissues (NSCLC P<0.001, LUAD P=0.017, and LUSC P=0.243) (Fig. 16A). In addition, hsa-miR-372-3p and HOX3A had 1 fragment of complementary sequences of ′3′CGUGAA5′-3′ GCACUU-5″ (Fig. 16B). Furthermore, the sensitivity and specificity of miR-372-3p expression in NSCLC were examined using the sROC method. The results suggested that the optimal sensitivity and specificity of a high miR-372-3p expression in the NSCLC group were SENS, 0.71 (0.57, 0.83) and SPES, 0.65 (0.52, 0.76), respectively, and the AUC was 0.73 (95% CI: 0.69, 0.77). The optimal sensitivity and specificity of the LUAD group were SENS, 0.65 (0.5, 0.77) and SPES, 0.66 (0.43, 0.83), respectively, and the AUC was 0.69 (95% CI: 0.65, 0.73) (Fig. 16C and D). Discussion This study used qPCR detection and TCGA RNA-seq data to confirm that HOXA3 expression was significantly down-regulated in LUAD tissues. The downregulation of HOXA3 may be closely associated with a more favourable prognosis of LUAD. In addition, the TCGA data indicated that HOXA3 harboured genetic alterations in 11–55% of LUAD tissues, and the methylation level of HOXA3 in LUAD tissues was significantly upregulated. Combined with the TCGA data, the upregulation of the HOXA3 level in LUSC was not significant. Therefore, we paid more attention to the clinical significance and molecular mechanisms of action of HOXA3 in LUAD. Through the collection of co-expression genes and GO and KEGG analyses, the preliminary results revealed that HOXA3 may play important roles in LUAD through the regulation of focal adhesion and ECM-receptor interaction signalling pathways. Furthermore, through the prediction of HOXA3 target miRNAs and meta-analyses of target miRNA expression based on the GEO microarray and TCGA data, the results confirmed that the expression of miR-372-3p that had complementary sequences with HOXA3 was significantly increased in LUAD tissues. There have been some studies of the association between the HOXA3 level and tumours. For example, Zhang et al (30) demonstrated that HOXA3 exhibited a high expression in both colorectal cancer tissues and cell lines. Shen et al (31) assessed the association between HOX family genes and nasopharyngeal carcinoma and demonstrated that HOXA3 expression was also upregulated. Kuasne et al (32) suggested that HOXA3 exhibited a low expression in penile carcinoma. At least to the best of our knowledge, only 1 methylation-related study on the association between HOXA3 and LUAD has been reported (19). This study, to the best of our knowledge, was the first to detect HOXA3 mRNA expression in LUAD. Combined with qPCR detection and TCGA data, we confirmed that HOXA3 expression was downregulated in LUAD tissues, and a low HOXA3 expression may play a important role in LUAD. The investigation of the association between HOXA3 and tumour progression has demonstrated that a high HOXA3 expression is associated with low survival rates in colon cancer (33). In penile carcinoma, a low HOXA3 expression was found to be associated with a poor prognosis (32). However, the association between HOXA3 and the progression of nasopharyngeal carcinoma has not been studied in depth (31). Our analyses of HOXA3 expression in all pathological stages of LUAD did not exhibit an obvious pattern. The survival analyses demonstrated that patients LUAD with a low HOXA3 expression had a better OS. Therefore, we hypothesized that the downregulation of HOXA3 expression may be an independent protective factor in LUAD. Furthermore, based on the microarray and RNA Seq data in TCGA, we preliminarily revealed that HOXA3 harboured a certain level of genetic alterations in LUAD tumour tissues. Thus, we would like to acquire more information for further validation. However, relevant studies are currently lacking, and literature reports are not available, at least to the best of our knowledge. As regards gene methylation, Kuasne et al performed genome-wide methylation studies on penile carcinoma and confirmed that 8 genes, including HOXA3, exhibited high methylation levels (32). In a validation study of epigenetic biomarkers in LUAD, Daugaard et al (19) performed genome-wide methylation microarray sequencing on 4 cases of LUAD tissues and normal cancer-adjacent lung tissues to screen differentially methylated genes in LUAD. They selected the 18 most significantly differentially methylated genes, including HOXA3, for validation in 52 samples. The methylation level of HOXA3 significantly increased (19). This study acquired HOXA3 methylation data from the TCGA database to perform analyses. The results suggested that the HOXA3 methylation level was significantly increased in LUAD tissues. This finding was consistent with the results in literature reports. Combined with HOXA3 mRNA expression levels in LUAD, the function of HOXA3 in LUAD may be associated with the increase in the methylation level. In addition, the study by Daugaard also demonstrated that the increase of HOXA3 methylation was even more evident in patients with tumour metastasis; however, its association with the prognostic survival rates in LUAD patients has not been elucidated (19). Despite the results of this study, sufficient evidence is not yet available to confirm the association between the methylation level of HOXA3 and LUAD progression. Thus, further studies are required for confirmation. As regards studies on the association between DNA methylation and mRNA expression, Kuasne et al (32) performed qPCR detection to demonstrate that genes with high methylation levels exhibited a low expression in penile carcinoma. These results confirmed that the methylation level and mRNA expression exhibited a negative correlation (32). Zhang et al performed cell experiments to confirm that a group of genes (S100P, GDA, WISP2, LOXL1, TIMP4, ICAM1, CLMP, HSP8, GAS1 and BMP2) exhibited a downregulated mRNA expression through high methylation levels to induce drug resistance in NSCLC (34). Jin et al demonstrated that 19 genes mediated the downregulation of mRNA expression through the increase in upstream methylation levels in LUAD (35). This study confirmed the low expression of HOXA3 in LUAD and the increase in the methylation level. Based on these findings, we hypothesized that HOXA3 methylation has a negative regulatory association with mRNA expression and plays critical roles in tumour development and progression. To investigate the underlying molecular mechanisms, GO and KEGG analyses were performed to compare the enrichment of HOXA3 co-expression genes between the NSCLC group and the LUAD group. The results demonstrated that the enrichment conditions in biological processes, cellular components, and molecular functions were basically the same. Some differences in the KEGG signalling pathways were noted. The LUAD group was more concentrated on the focal adhesion and ECM-receptor interaction pathways. HOXA3 may carry out its regulatory functions in LUAD through participation in these 2 signalling pathways. The focal adhesion signalling pathway is a critical pathway to activate focal adhesion kinase (FAK). Kinases activated by this pathway mainly mediate a variety of cellular metabolic processes, including cell metastasis, growth factor signal transduction, cell survival, cell cycle progression, and cell movement, and are closely associated with the development of malignant tumours (36–38). Currently, there are literature reports on using FAK as a novel potential biological target to investigate targeted therapy of NSCLC (39,40). The ECM-receptor interaction signalling pathway mediates the expression of enriched genes and regulates functions of these genes to promote tumour cell proliferation and migration and participate in tumour metastasis and infiltration (41,42). In NSCLC unrelated to smoking, the ECM-receptor interaction signalling pathway plays a critical role (43). The above-mentioned 2 signalling pathways significantly influence the development and progression of human malignant tumours and act as the bridge between abnormal gene expression and malignant tumour development. Therefore, in this study, we performed PPI analyses on genes enriched in the focal adhesion and ECM-receptor interaction signalling pathways and demonstrated that MAPK1, EGFR, TNC and COL1A1 served as core genes in these 2 pathways. In addition, based on the TCGA data, Pearson's correlation analyses demonstrated that only TNC and COL1A1 exhibited significantly positive correlations with HOXA3 expression in LUAD. One relevant study detected 72 cases of NSCLC tissues and normal lung tissues (44). TNC expression was upregulated in NSCLC and was closely associated with TNM stage, lymph node metastasis and tumour pleural invasion. Other studies have also demonstrated that TNC upregulation is associated with a poor prognosis in LUAD (45,46). The study by Oleksiewicz et al (47) on 156 cases of NSCLC and normal lung tissues revealed that COL1A1 was significantly overexpressed in tumour tissues. That study also performed cell experiments to confirm that COL1A1 was closely associated with hypoxia responses in NSCLC (47). Combined with bioinformatics analysis results, HOXA3 may collaborate with co-expression genes, such as TNC and COL1A1, to regulate focal adhesion and ECM-receptor interaction signalling pathways, thus carrying out is functions in LUAD. However, more functional studies are required for further validation. In this study, we also performed meta-analyses to confirm that the expression of the predicted miR-372-3p was upregulated in LUAD. Complementary sequences were noted between miR-372-3p and HOXA3. Combined with qPCR detection, HOXA3 and miR-372-3p expression exhibited a negative correlation trend in LUAD. The results of a literature search demonstrated that miR-372-3p was highly expressed in both testicular cancer and LUSC. miR-372-3p promotes cell growth and migration in LUSC through the downregulation of the target gene FGF9 (48,49). Therefore, based on results of this study and those of studies in the literature, we hypothesized that the downregulation of HOXA3 expression in LUAD tissues may be associated with the increase in miR-372-3p expression and HOXA3 may carry out its function through the targeted upregulation of miR-372-3p. However, this hypothesis needs to be validated using various experiments. In conclusion, combined with the RT-qPCR detection results and data from the TCGA and GEO databases, we confirmed that HOXA3 expression was downregulated in LUAD tissues and exhibited a certain level of genetic alteration. The functions of downregulated HOXA3 in tumour progression and a poor prognosis of patients with LUAD may be associated with increases in the methylation level. Furthermore, HOXA3 may collaborate with co-expression genes, such as TNC and COL1A1, to regulate the focal adhesion and ECM-receptor interaction signalling pathways together or upregulate miR-372-3p to promote its carcinogenesis function. These study results provide true and reliable experimental data and rigorous molecular theories for further studies on the molecular mechanisms of HOXA3 in LUAD. Acknowledgments The authors would like to thank all members of the Molecular Oncology Group of the First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi Zhuang Autonomous Region 530021, China) for their professional suggestions. Funding No funding was received. Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request. Authors' contributions BLG collected data from public datasets and analyzed the data and performed the statistical analysis. RQH and YZ collected the clinical samples and performed in-house RT-qPCR experiments. RQH and GC participated in the conception and design of the study and in language modification. BLG and RQH drafted the manuscript and analyzed the GO and KEGG terms. DMW and XHH conceived and designed the study and assisted in the drafting of the manuscript. All authors have read and approved the final manuscript. Ethics approval and consent to participate This research programme was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All participants signed informed consent forms. Patient consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Figure 1 Flow chart of the study design of this study. Figure 2 (A) Scatter diagram of HOXA3 expression between NSCLC tissue and normal lung tissue detected by RT-qPCR. (B) ROC curve of HOXA3 expression in NSCLC tissue. (C and D) Scatter plots of HOXA3 level in LUAD detected by RT-qPCR. (C) Differences between cancer and non-cancer. (D) Differences between smoker and non-smoker in LUAD. (E) HOXA3 expression between LUSC tissue and normal lung tissue detected by RT-qPCR. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. Figure 3 (A) Boxplot of HOXA3 expression in LUAD tissues vs. non-cancerous tissues and LUSC tissues vs. non-cancerous tissues; *P<0.05. (B) Pathological stage plot of HOXA3 levels in NSCLC. Panel a, NSCLC; panel b, LUAD; panel c, LUSC. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. Figure 4 (A) Survival curve of HOXA3 expression in NSCLC. Overall survival (OS: panel a, NSCLC; panel b, LUAD; panel c, LUSC) and disease-free survival (DFS: panel d, NSCLC; panel e, LUAD; panel f, LUSC). (B) The atlas of genetic alteration of HOXA3 mRNA in NSCLC. Panels a and b show HOXA3 mRNA expression z-scores by microarray and RNA Seq V2 RSEM in LUAD. Altered were 24 (5%) and 59 (11%) of 520 sequenced cases/patients (520 total) respectively; panels c, d and e show HOXA3 mRNA expression z-scores by U133 microarray only, microarray and RNA Seq V2 RSEM in LUSC. Altered were 18 (4%), 25 (5%) and 35 (7%) of 504 sequenced cases/patients (504 total). HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. Figure 5 Scatter plot of HOXA3 methylation levels between lung cancer tissues and normal lung tissues (A) NSCLC; (B) LUAD; (C) LUSC. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; ROC curve of HOXA3 methylation levels between lung cancer tissues and normal lung tissues (D) NSCLC; (E) LUAD; (F) LUSC. Figure 6 Network of gene ontology (GO) terms of HOXA3 co-expression genes in NSCLC constructed by cytoscape v3.5.0. (A-C) Show biological processes (BPs), cellular components (CCs) and molecular functions (MFs), respectively. In this network, only terms with statistically significant [P<0.01 (BP) or P<0.05 (CC and MF)] are displayed. Each node represents a GO term, and the node color indicates the P-value of a GO term. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer. Figure 7 (A) Network mappings were Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of HOXA3 co-expression genes in NSCLC. (B) The significant signalling pathways (P<0.05) enriched in HOXA3 co-expression genes in NSCLC constructed by ClueGO plugin. The color of the circles represents the degree of enrichment of the pathway (P-value). HOXA3, homeobox A3; NSCLC, non-small cell lung cancer. Figure 8 Significantly enriched annotation of GO categories and KEGG pathways of HOXA3 co-expression genes in NSCLC. (A) Biological processes (BPs); (B) Cellular components (CCs); (C) Molecular factors (MFs); (D) KEGG pathways. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; HOXA3, homeobox A3; NSCLC, non-small cell lung cancer. Figure 9 The network of GO terms of HOXA3 co-expression genes in LUAD were constructed by cytoscape v3.5.0. (A-C) Biological processes (BPs), cellular components (CCs) and molecular functions (MFs), respectively. In this network, only terms with statistically significant (P<0.05) are displayed. Each node represents a GO term, and the node color indicates the P-value of a GO term. GO, Gene Ontology; HOXA3, homeobox A3; LUAD, lung adenocarcinoma. Figure 10 (A) Network mappings of KEGG pathway anlaysis of HOXA3 co-expression genes in LUAD. (B) The significantly signalling pathways (P<0.05) enriched HOXA3 co-expression genes in LUAD constructed by the ClueGO plugin. The color of circles represents the P-value of the signalling pathways. HOXA3, homeobox A3; KEGG, Kyoto Encyclopedia of Genes and Genomes; LUAD, lung adenocarcinoma. Figure 11 Significantly enriched annotation of GO categories and KEGG pathways of HOXA3 co-expression genes in LUAD. (A) Biological processes (BPs); (B) Cellular components (CCs); (C) Molecular factors (MFs); (D) KEGG pathway. HOXA3, homeobox A3; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; LUAD, lung adenocarcinoma. Figure 12 (A) PPI network analysis of genes co-expressed in HOXA3 in NSCLC and (B) the genes most implicated by the signalling pathways. PPI, protein-protein interaction; HOXA3, homeobox A3; NSCLC, non-small cell lung cancer. Figure 13 PPI network analysis of genes co-expressed in HOXA3 in LUAD. PPI, protein-protein interaction; HOXA3, homeobox A3; LUAD, lung adenocarcinoma. Figure 14 Correlation between the hub genes and the expression of HOXA3 in NSCLC. (A) MAPK1; (B) EGFR; (C) COL1A1; (D) TNC. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer. Figure 15 Correlation between the hub genes and the expression of HOXA3 in LUAD. (A) MAPK1; (B) EGFR; (C) COL1A1; (D) TNC. HOXA3, homeobox A3; LUAD, lung adenocarcinoma. Figure 16 (A) Forest profile of SMD of miR-372-3p expression between NSCLC and normal lung tissue. (B) The complementary sequences existing between miR-372-3p and HOXA3. (C and D) The combined sROC curve for miR-372-3P expression between NSCLC and normal lung tissue; (C) NSCLC and (D) LUAD. HOXA3, homeobox A3; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma. Table I The association of between HOXA3 mRNA expression in NSCLC tissues and patient clinicopathological characteristics based on RT-qPCR detection. Clinicopathological characteristics Case no. HOXA3 expression t-test of data Mean SD FC t-test P-value Group  Control 55 0.19 0.20 1.00 2.86 0.006  Cancer 55 0.11 0.14 0.60 Pathological type  Adenocarcinoma 32 0.13 0.17 1.00 0.99 0.326  Squamous cell carcinoma 23 0.09 0.08 0.70 LUAD  Control 32 0.23 0.24 1.00 −1.94 0.023  Cancer 32 0.13 0.17 0.55 LUAD  Non-smoker 18 0.18 0.20 1.00 2.42 0.025  Smoker 14 0.06 0.04 0.32 LUSC  Control 23 0.12 0.09 1.00 −1.32 0.034  Cancer 23 0.09 0.08 0.73 Sex  Male 41 0.12 0.15 1.00 0.35 0.732  Female 14 0.10 0.12 0.87 Age (years)  <60 35 0.12 0.15 1.00 0.25 0.801  ≥60 20 0.11 0.12 0.91 Smoking  No 30 0.14 0.17 1.00 1.91 0.064  Yes 25 0.08 0.06 0.54 Size  ≤3 cm 16 0.12 0.12 1.00 0.09 0.931  >3 cm 39 0.11 0.15 0.97 LNM  No 29 0.08 0.10 1.00 −1.66 0.103  Yes 26 0.14 0.17 1.78 TNM  I–II 29 0.09 0.11 1.00 −1.26 0.212  III–IV 26 0.14 0.17 1.54 Vascular invasion  No 50 0.11 0.15 1.00 0.23 0.817  Yes 5 0.10 0.03 0.85 Clinical grading  I 5 0.09 0.08 0.664  II 40 0.12 0.16  III 10 0.08 0.07 HOXA3, homeobox A3, an mRNA of homeobox genes of clusters A; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; SD, standard deviation; FC, fold change; LNM, lymph node metastasis. An independent sample t-test was adopted to test the data and single factor ANOVA was used to test the clinical grading data. The difference between the cancer and normal adjacent group was analyzed by a paired-samples t-test. Table II The association of between the HOXA3 mRNA methylation level in NSCLC tissues and normal adjacent tissues base on the TCGA data. Histological type Case no. HOXA3 methylation level t-test of data Mean SD FC t-test P-value NSCLC  Normal adjacent 86 0.43 0.11 1.00 9.89 <0.001  Cancer 744 0.57 0.21 1.32 LUAD  Normal adjacent 43 0.44 0.11 1.00 6.19 <0.001  Cancer 372 0.56 0.20 1.27 LUSC  Normal adjacent 43 0.42 0.11 1.00 7.72 <0.001  Cancer 372 0.58 0.21 1.38 HOXA3, homeobox A3, an mRNA of homeobox genes of clusters A; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. Table III The top ten most significant items of Gene Ontology (GO) terms of the co-expression genes of homeobox A3 (HOXA3) in non-small cell lung cancer. Category Term Count P-value FDR Biological processes GOTERM_BP_FAT GO:0048706~embryonic skeletal system development 8 3.41E-05 0.06 GOTERM_BP_FAT GO:0001501~skeletal system development 14 1.07E-04 0.18 GOTERM_BP_FAT GO:0045682~regulation of epidermis development 5 1.17E-04 0.19 GOTERM_BP_FAT GO:0030334~regulation of cell migration 10 1.80E-04 0.30 GOTERM_BP_FAT GO:0042981~regulation of apoptosis 23 1.97E-04 0.33 GOTERM_BP_FAT GO:0043067~regulation of programmed cell death 23 2.27E-04 0.38 GOTERM_BP_FAT GO:0010941~regulation of cell death 23 2.39E-04 0.40 GOTERM_BP_FAT GO:0048705~skeletal system morphogenesis 8 3.64E-04 0.60 GOTERM_BP_FAT GO:0040012~regulation of locomotion 10 4.64E-04 0.77 GOTERM_BP_FAT GO:0051270~regulation of cell motion 10 4.81E-04 0.80 Cellular components GOTERM_CC_FAT GO:0005626~insoluble fraction 22 0.000184 0.24 GOTERM_CC_FAT GO:0005624~membrane fraction 20 0.000837 1.07 GOTERM_CC_FAT GO:0031012~extracellular matrix 12 0.001071 1.37 GOTERM_CC_FAT GO:0044420~extracellular matrix part 7 0.001490 1.90 GOTERM_CC_FAT GO:0045177~apical part of cell 8 0.002892 3.66 GOTERM_CC_FAT GO:0000267~cell fraction 22 0.004675 5.86 GOTERM_CC_FAT GO:0042995~cell projection 16 0.006747 8.35 GOTERM_CC_FAT GO:0005578~proteinaceous extracellular matrix 10 0.006859 8.48 GOTERM_CC_FAT GO:0016324~apical plasma membrane 6 0.013372 15.92 GOTERM_CC_FAT GO:0016323~basolateral plasma membrane 7 0.020688 23.61 Molecular functional GOTERM_MF_FAT GO:0043565~sequence-specific DNA binding 20 0.000041 0.06 GOTERM_MF_FAT GO:0008047~enzyme activator activity 11 0.004149 5.55 GOTERM_MF_FAT GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding 3 0.004179 5.59 GOTERM_MF_FAT GO:0016641~oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor 3 0.010187 13.11 GOTERM_MF_FAT GO:0030695~GTPase regulator activity 11 0.014540 18.21 GOTERM_MF_FAT GO:0016638~oxidoreductase activity, acting on the CH-NH2 group of donors 3 0.016640 20.58 GOTERM_MF_FAT GO:0060589~nucleoside-triphosphatase regulator activity 11 0.016712 20.66 GOTERM_MF_FAT GO:0035091~phosphoinositide binding 5 0.025094 29.45 GOTERM_MF_FAT GO:0016208~AMP binding 3 0.028747 33.00 GOTERM_MF_FAT GO:0003779~actin binding 9 0.028844 33.09 Table IV KEGG pathways enriched by co-expression genes of homeobox A3 (HOXA3) mRNA in non-small cell lung cancer. Category Term Count P-value FDR KEGG_PATHWAY hsa04510:Focal adhesion 12 0.001 0.76 KEGG_PATHWAY hsa05200:Pathways in cancer 15 0.001 1.67 KEGG_PATHWAY hsa04350:TGF-beta signaling pathway 7 0.004 4.34 KEGG_PATHWAY hsa04540:Gap junction 7 0.004 4.84 KEGG_PATHWAY hsa04010:MAPK signaling pathway 12 0.006 7.01 KEGG_PATHWAY hsa05218:Melanoma 6 0.008 8.33 KEGG_PATHWAY hsa05212:Pancreatic cancer 6 0.008 8.81 KEGG_PATHWAY hsa05220:Chronic myeloid leukemia 6 0.010 10.36 KEGG_PATHWAY hsa05222:Small cell lung cancer 6 0.015 15.93 KEGG_PATHWAY hsa05210:Colorectal cancer 6 0.015 15.93 KEGG_PATHWAY hsa04512:ECM-receptor interaction 6 0.015 15.93 KEGG_PATHWAY hsa05215:Prostate cancer 6 0.019 19.63 KEGG_PATHWAY hsa04912:GnRH signaling pathway 6 0.028 27.23 KEGG_PATHWAY hsa04916:Melanogenesis 6 0.029 28.15 KEGG_PATHWAY hsa04060:Cytokine-cytokine receptor interaction 10 0.039 35.71 Table V The top 10 most significant items of Gene Ontology (GO) terms of the co-expression genes of homeobox A3 (HOXA3) mRNA in lung adenocarcinoma. Category Term Count P-value FDR Biological Processes GOTERM_BP_FAT GO:0048706~embryonic skeletal system development 8 3.41E-05 0.056837 GOTERM_BP_FAT GO:0001501~skeletal system development 14 1.07E-04 0.178201 GOTERM_BP_FAT GO:0045682~regulation of epidermis development 5 1.17E-04 0.194494 GOTERM_BP_FAT GO:0030334~regulation of cell migration 10 1.80E-04 0.299680 GOTERM_BP_FAT GO:0042981~regulation of apoptosis 23 1.97E-04 0.328453 GOTERM_BP_FAT GO:0043067~regulation of programmed cell death 23 2.27E-04 0.377505 GOTERM_BP_FAT GO:0010941~regulation of cell death 23 2.39E-04 0.397502 GOTERM_BP_FAT GO:0048705~skeletal system morphogenesis 8 3.64E-04 0.604848 GOTERM_BP_FAT GO:0040012~regulation of locomotion 10 4.64E-04 0.770756 GOTERM_BP_FAT GO:0051270~regulation of cell motion 10 4.81E-04 0.798787 Cellular ψomponents GOTERM_CC_FAT GO:0005626~insoluble fraction 22 0.000184 0.237025 GOTERM_CC_FAT GO:0005624~membrane fraction 20 0.000837 1.072817 GOTERM_CC_FAT GO:0031012~extracellular matrix 12 0.001071 1.370868 GOTERM_CC_FAT GO:0044420~extracellular matrix part 7 0.001490 1.902184 GOTERM_CC_FAT GO:0045177~apical part of cell 8 0.002892 3.662636 GOTERM_CC_FAT GO:0000267~cell fraction 22 0.004675 5.857488 GOTERM_CC_FAT GO:0042995~cell projection 16 0.006747 8.351548 GOTERM_CC_FAT GO:0005578~proteinaceous extracellular matrix 10 0.006859 8.483923 GOTERM_CC_FAT GO:0016324~apical plasma membrane 6 0.013372 15.921503 GOTERM_CC_FAT GO:0016323~basolateral plasma membrane 7 0.020688 23.607821 Molecular ϕunctional GOTERM_MF_FAT GO:0043565~sequence-specific DNA binding 20 0.000041 0.056109 GOTERM_MF_FAT GO:0008047~enzyme activator activity 11 0.004149 5.548392 GOTERM_MF_FAT GO:0005547~phosphatidylinositol-3,4,5-trisphosphate binding 3 0.004179 5.587211 GOTERM_MF_FAT GO:0016641~oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor 3 0.010187 13.113973 GOTERM_MF_FAT GO:0030695~GTPase regulator activity 11 0.014540 18.214548 GOTERM_MF_FAT GO:0016638~oxidoreductase activity, acting on the CH-NH2 group of donors 3 0.016640 20.575093 GOTERM_MF_FAT GO:0060589~nucleoside-triphosphatase regulator activity 11 0.016712 20.655661 GOTERM_MF_FAT GO:0035091~phosphoinositide binding 5 0.025094 29.453780 GOTERM_MF_FAT GO:0016208~AMP binding 3 0.028747 32.997529 GOTERM_MF_FAT GO:0003779~actin binding 9 0.028844 33.089357 Table VI KEGG pathway enriched by co-expression genes of homeobox A3 (HOXA3) mRNA in lung adenocarcinoma. Category Term Count P-value FDR KEGG_PATHWAY hsa04510:Focal adhesion 12 3.84E-05 0.042706 KEGG_PATHWAY hsa04512:ECM-receptor interaction 6 0.004145 4.514261 KEGG_PATHWAY hsa05218:Melanoma 5 0.012451 13.009202 KEGG_PATHWAY hsa05212:Pancreatic cancer 5 0.013063 13.603250 KEGG_PATHWAY hsa05210:Colorectal cancer 5 0.021874 21.802852 KEGG_PATHWAY hsa05222:Small cell lung cancer 5 0.021874 21.802852 KEGG_PATHWAY hsa05200:Pathways in cancer 10 0.022490 22.349251 KEGG_PATHWAY hsa05215:Prostate cancer 5 0.026406 25.738703 KEGG_PATHWAY hsa05223:Non-small cell lung cancer 4 0.031134 29.652037 KEGG_PATHWAY hsa05214:Glioma 4 0.045993 40.760927 KEGG_PATHWAY hsa04010:MAPK signaling pathway 8 0.052597 45.164053 KEGG_PATHWAY hsa05220:Chronic myeloid leukemia 4 0.070302 55.541161 KEGG_PATHWAY hsa04144:Endocytosis 6 0.084942 62.734617 KEGG_PATHWAY hsa04350:TGF-beta signaling pathway 4 0.099275 68.735075 KEGG_PATHWAY hsa04012:ErbB signaling pathway 4 0.099275 68.735075 Table VII Top 10 with combined co-expression score that the protein-protein interaction (PPI) of homeobox A3 (HOXA3) co-expression genes in non-small cell lung cancer. #Node1 Node2 Node1 STRING internal ID Homology Co-expression Experimentally determined interaction Automated text mining Combined score STX2 SNAP25 1858001 0 0.093 0.939 0.905 0.998 CDKN2B CDK6 1846519 0 0.054 0.432 0.763 0.985 DUSP10 MAPK1 1854467 0 0.053 0.498 0.705 0.984 CALD1 MYLK 1854225 0 0.248 0 0.791 0.982 MITF MAPK1 1847592 0 0.048 0.395 0.733 0.982 ARRB1 MAPK1 1860799 0 0 0.43 0.658 0.978 ITSN1 ITSN2 1857363 0.965 0 0.702 0.726 0.969 EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 MALT1 CARD10 1850132 0 0 0.115 0.63 0.964 RUNX2 MAPK1 1855482 0 0 0 0.639 0.962 Table VIII Top 10 with combined co-expression score that the protein-protein interaction (PPI) of homeobox A3 (HOXA3) co-expression gene intersection in non-small cell lung cancer enriched in significant signalling pathways. #Node1 Node2 Node1 STRING internal ID Homology Co-expression Experimentally determined interaction Automated text mining Combined score EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 COL6A1 COL1A1 1854318 0.617 0.504 0 0.49 0.957 MYLK MAPK1 1853981 0.636 0 0 0.711 0.925 LAMA3 LAMA4 1850649 0.804 0 0 0.115 0.901 PDGFD EGFR 1858075 0 0 0 0.49 0.893 EGFR TNC 1846445 0 0 0.36 0.72 0.813 THBS1 COL1A1 1844779 0 0.1 0.324 0.463 0.645 TNC MAPK1 1845696 0 0 0 0.576 0.576 TNC THBS1 1845696 0 0.052 0 0.533 0.538 FLNC MAPK1 1850897 0 0 0.066 0.475 0.49 EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 COL6A1 COL1A1 1854318 0.617 0.504 0 0.49 0.957 MYLK MAPK1 1853981 0.636 0 0 0.711 0.925 LAMA3 LAMA4 1850649 0.804 0 0 0.115 0.901 PDGFD EGFR 1858075 0 0 0 0.49 0.893 Table IX Top 10 with combined score co-expression correlation by STRING 10.5 of homeobox A3 (HOXA3) co-expression genes in lung adenocarcinoma. #Node1 Node2 Node1 STRING internal ID Homology Co-expression Experimentally determined interaction Automated text mining Combined score STX2 SNAP25 1858001 0 0.093 0.939 0.905 0.998 ARRB1 MAPK1 1860799 0 0 0.43 0.658 0.978 EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 MALT1 CARD10 1850132 0 0 0.115 0.63 0.964 COL6A1 COL1A1 1854318 0.617 0.504 0 0.49 0.957 PDE10A ADCY6 1862089 0 0.207 0.169 0.384 0.954 ARRB1 EGFR 1860799 0 0 0.165 0.416 0.947 EGFR CFTR 1846445 0 0 0 0.445 0.942 EGFR ERBB3 1846445 0.921 0.05 0.36 0.956 0.938 TGFB2 THBS1 1854475 0 0.046 0 0.364 0.934 STX2 SNAP25 1858001 0 0.093 0.939 0.905 0.998 ARRB1 MAPK1 1860799 0 0 0.43 0.658 0.978 EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 MALT1 CARD10 1850132 0 0 0.115 0.63 0.964 COL6A1 COL1A1 1854318 0.617 0.504 0 0.49 0.957 Table X Top 10 with combined co-expression score that the protein-protein interaction (PPI) of homeobox A3 (HOXA3) co-expression gene intersection in lung adenocarcinoma enriched in significant signalling pathways. #Node1 Node2 Node1 STRING internal ID Homology Co-expression Experimentally determined interaction Automated text mining Combined score EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 COL6A1 COL1A1 1854318 0.617 0.504 0 0.49 0.957 MYLK MAPK1 1853981 0.636 0 0 0.711 0.925 LAMA3 LAMA4 1850649 0.804 0 0 0.115 0.901 PDGFD EGFR 1858075 0 0 0 0.49 0.893 EGFR TNC 1846445 0 0 0.36 0.72 0.813 THBS1 COL1A1 1844779 0 0.1 0.324 0.463 0.645 TNC MAPK1 1845696 0 0 0 0.576 0.576 TNC THBS1 1845696 0 0.052 0 0.533 0.538 FLNC MAPK1 1850897 0 0 0.066 0.475 0.49 AKT3 MAPK1 1845421 0.65 0.134 0.292 0.576 0.486 EGFR THBS1 1846445 0 0 0 0.457 0.457 COL6A1 TNC 1854318 0 0.055 0 0.424 0.432 TNC COL1A1 1845696 0 0.1 0 0.369 0.408 EGFR MAPK1 1846445 0.632 0 0.503 0.932 0.965 ==== Refs References 1 Siegel RL Miller KD Jemal A Cancer Statistics, 2017 CA Cancer J Clin 67 7 30 2017 10.3322/caac.21387 28055103 2 Cancer UK: Lung cancer mortality statistics 2014 3 Chen W Zheng R Baade PD Zhang S Zeng H Bray F Jemal A Yu XQ He J Cancer statistics in China, 2015 CA Cancer J Clin 66 115 132 2016 10.3322/caac.21338 26808342 4 Miller KD Siegel RL Lin CC Mariotto AB Kramer JL Rowland JH Stein KD Alteri R Jemal A Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 66 271 289 2016 10.3322/caac.21349 27253694 5 Govindan R Page N Morgensztern D Read W Tierney R Vlahiotis A Spitznagel EL Piccirillo J Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 4539 4544 2006 10.1200/JCO.2005.04.4859 17008692 6 O'Brien TD Jia P Caporaso NE Landi MT Zhao Z Weak sharing of genetic association signals in three lung cancer subtypes: Evidence at the SNP, gene, regulation, and pathway levels Genome Med 10 16 2018 10.1186/s13073-018-0522-9 29486777 7 Abraham C Garsa A Badiyan SN Drzymala R Yang D DeWees T Tsien C Dowling JL Rich KM Chicoine MR Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS) Adv Radiat Oncol 3 146 153 2017 10.1016/j.adro.2017.11.003 29904739 8 Fernandes P Lareiro S Vouga L Guerra M Miranda J Uniportal video-assisted thorascoscopic surgery - The new paradigm in the surgical treatment of lung cancer Rev Port Cir Cardiotorac Vasc 24 127 2017 9 Jean F Tomasini P Barlesi F Atezolizumab: Feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy Ther Adv Med Oncol 9 769 779 2017 10.1177/1758834017741074 29449897 10 Jiang Q Xie M He M Yan F Zhang X Yu S Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer Oncotarget 9 7672 7683 2017 29484143 11 Byrne M Martinez P Morris V Evolution of a pentameral body plan was not linked to translocation of anterior Hox genes: The echinoderm HOX cluster revisited Evol Dev 18 137 143 2016 10.1111/ede.12172 26763653 12 Kim HS Kim BM Lee BY Souissi S Park HG Lee JS Identification of Hox genes and rearrangements within the single homeobox (Hox) cluster (192.8 kb) of the cyclopoid copepod (Paracyclopina nana) J Exp Zoolog B Mol Dev Evol 326 105 109 2016 10.1002/jez.b.22668 13 Schiemann SM Martín-Durán JM Børve A Vellutini BC Passamaneck YJ Hejnol A Clustered brachiopod Hox genes are not expressed collinearly and are associated with lophotrochozoan novelties Proc Natl Acad Sci USA 114 E1913 E1922 2017 10.1073/pnas.1614501114 28228521 14 Wang X Bu J Liu X Wang W Mai W Lv B Zou J Mo X Li X Wang J miR-133b suppresses metastasis by targeting HOXA9 in human colorectal cancer Oncotarget 8 63935 63948 2017 28969042 15 Wang K Jin J Ma T Zhai H MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9 J Cell Mol Med 21 3730 3740 2017 10.1111/jcmm.13282 28780773 16 Fu Z Chen C Zhou Q Wang Y Zhao Y Zhao X Li W Zheng S Ye H Wang L LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9 Cancer Lett 410 68 81 2017 10.1016/j.canlet.2017.09.019 28947139 17 Chen S Yu J Lv X Zhang L HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo Cell Biochem Funct 35 433 440 2017 10.1002/cbf.3293 28961318 18 Sang Y Zhou F Wang D Bi X Liu X Hao Z Li Q Zhang W Up-regulation of long non-coding HOTTIP functions as an oncogene by regulating HOXA13 in non-small cell lung cancer Am J Transl Res 8 2022 2032 2016 27347311 19 Daugaard I Dominguez D Kjeldsen TE Kristensen LS Hager H Wojdacz TK Hansen LL Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma Sci Rep 6 35807 2016 10.1038/srep35807 27782156 20 Zhang Y Chen WJ Gan TQ Zhang XL Xie ZC Ye ZH Deng Y Wang ZF Cai KT Li SK Clinical significance and effect of lncRNA HOXA11-AS in NSCLC: A study based on bioinformatics, in vitro and in vivo verification Sci Rep 7 5567 2017 10.1038/s41598-017-05856-2 28717185 21 Tang RX Chen WJ He RQ Zeng JH Liang L Li SK Ma J Luo DZ Chen G Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma Oncotarget 8 50761 50773 2017 28881601 22 Li Z Xie Y Zhong T Zhang X Dang Y Gan T Chen G Expression and clinical contribution of MRGD mRNA in non-small cell lung cancers J BUON 20 1101 1106 2015 26416063 23 Muraoka T Soh J Toyooka S Aoe K Fujimoto N Hashida S Maki Y Tanaka N Shien K Furukawa M The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma Lung Cancer 82 485 490 2013 10.1016/j.lungcan.2013.09.017 24168922 24 Singh J Batish VK Grover S Simultaneous detection of Listeria monocytogenes and Salmonella spp. in dairy products using real time PCR-melt curve analysis J Food Sci Technol 49 234 239 2012 10.1007/s13197-011-0278-3 23572847 25 Xu D Yang Z Zhang D Wu W Guo Y Chen Q Xu D Cui W Rapid detection of immunoglobulin heavy chain gene rearrangement by PCR and melting curve analysis using combined FR2 and FR3 primers Diagn Pathol 10 140 2015 10.1186/s13000-015-0370-5 26255311 26 Zaghloul H El Morsi AA Soweha HE Elsayed A Seif S El-Sharawy H A simple real-time polymerase chain reaction assay using SYBR Green for hepatitis C virus genotyping Arch Virol 162 57 61 2017 10.1007/s00705-016-3059-5 27664028 27 Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 402 408 2001 10.1006/meth.2001.1262 11846609 28 Tang R Liang L Luo D Feng Z Huang Q He R Gan T Yang L Chen G Downregulation of miR-30a is associated with poor prognosis in lung cancer Med Sci Monit 21 2514 2520 2015 10.12659/MSM.894372 26305739 29 Ren F Ding H Huang S Wang H Wu M Luo D Dang Y Yang L Chen G Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues Cancer Cell Int 15 80 2015 10.1186/s12935-015-0227-8 26257582 30 Zhang X Liu G Ding L Jiang T Shao S Gao Y Lu Y HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway J Cell Biochem 119 2864 2874 2018 10.1002/jcb.26461 29073728 31 Shen ZH Zhao KM Du T HOXA10 promotes nasopharyngeal carcinoma cell proliferation and invasion via inducing the expression of ZIC2 Eur Rev Med Pharmacol Sci 21 945 952 2017 28338202 32 Kuasne H Cólus IM Busso AF Hernandez-Vargas H Barros-Filho MC Marchi FA Scapulatempo-Neto C Faria EF Lopes A Guimarães GC Genome-wide methylation and transcriptome analysis in penile carcinoma: Uncovering new molecular markers Clin Epigenetics 7 46 2015 10.1186/s13148-015-0082-4 25908946 33 Zhang X Liu G Ding L Jiang T Shao S Gao Y Lu Y HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway J Cell Biochem 119 2864 2874 2018 10.1002/jcb.26461 29073728 34 Zhang YW Zheng Y Wang JZ Lu XX Wang Z Chen LB Guan XX Tong JD Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer Epigenetics 9 896 909 2014 10.4161/epi.28601 24699858 35 Jin X Liu X Li X Guan Y Integrated analysis of DNA methylation and mRNA expression profiles data to identify key Genes in lung adenocarcinoma Biomed Res Int 2016 4369431 2016 10.1155/2016/4369431 27610375 36 Tai YL Chen LC Shen TL Emerging roles of focal adhesion kinase in cancer Biomed Res Int 2015 690690 2015 10.1155/2015/690690 25918719 37 Min A Zhu C Wang J Peng S Shuai C Gao S Tang Z Su T Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression J Biochem Mol Toxicol 29 70 76 2015 10.1002/jbt.21669 25199511 38 Eke I Cordes N Focal adhesion signaling and therapy resistance in cancer Semin Cancer Biol 31 65 75 2015 10.1016/j.semcancer.2014.07.009 25117005 39 Zhou B Wang GZ Wen ZS Zhou YC Huang YC Chen Y Zhou GB Somatic mutations and splicing variants of focal adhesion kinase in non-small cell lung cancer J Natl Cancer Inst 110 195 204 2017 10.1093/jnci/djx157 40 Tang KJ Constanzo JD Venkateswaran N Melegari M Ilcheva M Morales JC Skoulidis F Heymach JV Boothman DA Scaglioni PP Focal adhesion kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer Clin Cancer Res 22 5851 5863 2016 10.1158/1078-0432.CCR-15-2603 27220963 41 Zhang HJ Tao J Sheng L Hu X Rong RM Xu M Zhu TY Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway Onco Targets Ther 9 1801 1812 2016 27099513 42 Zhang H Ye J Weng X Liu F He L Zhou D Liu Y Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma Cancer Genet 208 482 491 2015 10.1016/j.cancergen.2015.06.002 26271415 43 Lv M Wang L Comprehensive analysis of genes, pathways, and TFs in nonsmoking Taiwan females with lung cancer Exp Lung Res 41 74 83 2015 10.3109/01902148.2014.971472 25514196 44 GE ZH Cheng QS LI WM Feng Z Wen MM Wang WC Zhang ZP Expression of TNC in NSCLC and its clinical significance Xiandai Shengwu Yixue Jinzhan 31 6103 6106 2014 In Chinese 45 Gocheva V Naba A Bhutkar A Guardia T Miller KM Li CM Dayton TL Sanchez-Rivera FJ Kim-Kiselak C Jailkhani N Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival Proc Natl Acad Sci USA 114 E5625 E5634 2017 10.1073/pnas.1707054114 28652369 46 Edlund K Lindskog C Saito A Berglund A Pontén F Göransson-Kultima H Isaksson A Jirström K Planck M Johansson L CD99 is a novel prognostic stromal marker in non-small cell lung cancer Int J Cancer 131 2264 2273 2012 10.1002/ijc.27518 22392539 47 Oleksiewicz U Liloglou T Tasopoulou KM Daskoulidou N Gosney JR Field JK Xinarianos G COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer J Cancer Res Clin Oncol 143 1133 1141 2017 10.1007/s00432-017-2381-y 28258342 48 Wang Q Liu S Zhao X Wang Y Tian D Jiang W MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma Cancer Med 6 1323 1330 2017 10.1002/cam4.1026 28440022 49 Syring I Bartels J Holdenrieder S Kristiansen G Müller SC Ellinger J Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer J Urol 193 331 337 2015 10.1016/j.juro.2014.07.010 25046619